Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | MARS1 | P56192 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033542 | 0.87 | ESR1 (0.57) | ESR1KMOMAPK8MARS1MAT2A | |
| SCHEMBL4032548 | 0.86 | ESR1 (0.55) | ESR1KMOALOX5MAPTKDM4C | |
| SCHEMBL5400293 | 0.83 | MAPT (0.50) | ESR1KMOMARS1MAPT | |
| SCHEMBL4030028 | 0.82 | ESR1 (0.47) | ESR1MARS1RORCMAPT | |
| SCHEMBL4025242 | 0.81 | ESR1 (0.44) | ESR1RORC | |
| SCHEMBL4032378 | 0.81 | ESR1 (0.44) | ESR1ALOX5MARS1RORC | |
| SCHEMBL4033245 | 0.81 | ESR1 (0.44) | ESR1ALOX5MARS1RORC | |
| SCHEMBL4203517 | 0.80 | ESR1 (0.64) | ESR1KMOSPRMARS1 | |
| SCHEMBL4197102 | 0.74 | ESR1 (0.44) | ESR1RORCMAPT | |
| SCHEMBL4032520 | 0.73 | ESR1 (0.60) | ESR1KMOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885KMO 2213/4885ALOX5 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.